Literature DB >> 14966128

Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif.

Huang Shao1, Xuejun Xu, Mary-Ann A Mastrangelo, Naijie Jing, Richard G Cook, Glen B Legge, David J Tweardy.   

Abstract

Stat3 is an Src homology (SH)2-containing protein constitutively activated in a wide variety of human cancers following its recruitment to YXXQ-containing motifs, which results in resistance to apoptosis. Despite resolution of the crystal structure of Stat3 homodimer bound to DNA, the structural basis for the unique specificity of Stat3 SH2 for YXXQ-containing phosphopeptides remains unresolved. We tested three models of this interaction based on computational analysis of available structures and sequence alignments, two of which assumed an extended peptide configuration and one in which the peptide had a beta-turn. By using peptide immunoblot affinity assays and mirror resonance affinity analysis, we demonstrated that only phosphotyrosine (Tyr(P)) peptides containing +3 Gln (not Leu, Met, Glu, or Arg) bound to wild type Stat3. Examination of a series of wild type and mutant Stat3 proteins demonstrated loss of binding to pYXXQ-containing peptides only in Stat3 mutated at Lys-591 or Arg-609, whose side chains interact with the Tyr(P) residue, and Stat3 mutated at Glu-638, whose amide hydrogen bonds with oxygen within the +3 Gln side chain when the peptide ligand assumes a beta-turn. These findings support a model for Stat3 SH2 interactions that could form the basis for anticancer drugs that specifically target Stat3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966128     DOI: 10.1074/jbc.M314037200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

Authors:  Pijus K Mandal; Donald Limbrick; David R Coleman; Garrett A Dyer; Zhiyong Ren; J Sanderson Birtwistle; Chiyi Xiong; Xiaomin Chen; James M Briggs; John S McMurray
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

2.  Activation of the STAT6 transcription factor in Jurkat T-cells by the herpesvirus saimiri Tip protein.

Authors:  Yuri Kim; Eun-Kyung Kwon; Ju-Hong Jeon; Insuk So; In-Gyu Kim; Myung-Sik Choi; Ik-Sang Kim; Joong-Kook Choi; Jae Ung Jung; Nam-Hyuk Cho
Journal:  J Gen Virol       Date:  2011-10-19       Impact factor: 3.891

3.  Nuclear import of the DSCAM-cytoplasmic domain drives signaling capable of inhibiting synapse formation.

Authors:  Sonja M Sachse; Sam Lievens; Luís F Ribeiro; Dan Dascenco; Delphine Masschaele; Katrien Horré; Anke Misbaer; Nele Vanderroost; Anne Sophie De Smet; Evgenia Salta; Maria-Luise Erfurth; Yoshiaki Kise; Siegfried Nebel; Wouter Van Delm; Stéphane Plaisance; Jan Tavernier; Bart De Strooper; Joris De Wit; Dietmar Schmucker
Journal:  EMBO J       Date:  2019-02-11       Impact factor: 11.598

4.  Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Authors:  Jianyong Chen; Longchuan Bai; Denzil Bernard; Zaneta Nikolovska-Coleska; Cindy Gomez; Jian Zhang; Han Yi; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2010-05-13       Impact factor: 4.345

5.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

6.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification.

Authors:  Anna A Dudka; Steve M M Sweet; John K Heath
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

7.  ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3.

Authors:  Yong-Sik Bong; Hyun-Shik Lee; Laura Carim-Todd; Kathleen Mood; Tagvor G Nishanian; Lino Tessarollo; Ira O Daar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

8.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012

Review 9.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

10.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.

Authors:  Khandaker Siddiquee; Shumin Zhang; Wayne C Guida; Michelle A Blaskovich; Benjamin Greedy; Harshani R Lawrence; M L Richard Yip; Richard Jove; Mark M McLaughlin; Nicholas J Lawrence; Said M Sebti; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.